1440.1 - PD-L1 testing for access to pembrolizumab in treatment na´ve patients with locally advanced or metastatic non-small cell lung cancer

Page last updated: 15 June 2018

Application Detail

Status

Open

Description of Medical Service

ImmunoHistoChemistry test for evaluation of Programmed Cell Death Ligand 1 (PD-L1) expression to determine eligibility for treatment with pembrolizumab

Description of Medical Condition

Locally advanced or metastatic non-small cell lung cancer

Reason for Application

New MBS item

Medical Service Type

Investigative

Previous Application Number

1440

Associated Documentation

Application Form

-

Consultation Survey

-

PICO Confirmation

see Application 1440

Assessment Report

-

Public Summary Document

Public Summary Document (PDF 106 KB)
Public Summary Document (Word 106 KB)

Meetings for this Application

PASC

-

ESC

-

MSAC

23 November 2017
28-29 March 2018